[go: up one dir, main page]

WO2000060355A3 - Site de liaison regulateur de lfa-1 (antigene de la fonction leucocytaire 1) et utilisations correspondantes - Google Patents

Site de liaison regulateur de lfa-1 (antigene de la fonction leucocytaire 1) et utilisations correspondantes Download PDF

Info

Publication number
WO2000060355A3
WO2000060355A3 PCT/US2000/008841 US0008841W WO0060355A3 WO 2000060355 A3 WO2000060355 A3 WO 2000060355A3 US 0008841 W US0008841 W US 0008841W WO 0060355 A3 WO0060355 A3 WO 0060355A3
Authority
WO
WIPO (PCT)
Prior art keywords
lfa
binding site
regulatory binding
regulatory
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/008841
Other languages
English (en)
Other versions
WO2000060355A2 (fr
Inventor
Donald Staunton
Der Vieren Monica Van
Jeff Huth
Kerry Fowler
Mark Orme
Edward T Olejniczak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Icos Corp
Original Assignee
Abbott Laboratories
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories, Icos Corp filed Critical Abbott Laboratories
Priority to EP00921627A priority Critical patent/EP1175615A2/fr
Priority to AU41920/00A priority patent/AU4192000A/en
Publication of WO2000060355A2 publication Critical patent/WO2000060355A2/fr
Publication of WO2000060355A3 publication Critical patent/WO2000060355A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur des procédés visant à réguler négativement la liaison de LFA-1 à un ICAM qui lie LFA-1, ainsi que un nouveau site de liaison régulateur sur LFA-1.
PCT/US2000/008841 1999-04-02 2000-04-03 Site de liaison regulateur de lfa-1 (antigene de la fonction leucocytaire 1) et utilisations correspondantes Ceased WO2000060355A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00921627A EP1175615A2 (fr) 1999-04-02 2000-04-03 Site de liaison regulateur de lfa-1 (antigene de la fonction leucocytaire 1) et utilisations correspondantes
AU41920/00A AU4192000A (en) 1999-04-02 2000-04-03 Lfa-1 regulatory binding site and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28547799A 1999-04-02 1999-04-02
US09/285,477 1999-04-02

Publications (2)

Publication Number Publication Date
WO2000060355A2 WO2000060355A2 (fr) 2000-10-12
WO2000060355A3 true WO2000060355A3 (fr) 2001-02-08

Family

ID=23094406

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/008841 Ceased WO2000060355A2 (fr) 1999-04-02 2000-04-03 Site de liaison regulateur de lfa-1 (antigene de la fonction leucocytaire 1) et utilisations correspondantes

Country Status (3)

Country Link
EP (1) EP1175615A2 (fr)
AU (1) AU4192000A (fr)
WO (1) WO2000060355A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521619B2 (en) 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
CA2414461A1 (fr) 2000-06-29 2002-01-10 Abbott Laboratories Derives d'aryle phenylheterocyclyle sulfures et leur utilisation en tant qu'agents immunosuppresseurs anti-inflammatoires inhibant l'adherence cellulaire
US7153944B2 (en) * 2000-07-31 2006-12-26 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
US7323552B2 (en) 2000-07-31 2008-01-29 The General Hospital Corporation Variant integrin polypeptides and uses thereof
US7064180B2 (en) 2000-07-31 2006-06-20 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
JP2004504827A (ja) * 2000-07-31 2004-02-19 ザ　ジェネラル　ホスピタル　コーポレーション 高親和性インテグリンポリペプチドおよびその使用方法
WO2004007444A2 (fr) 2002-07-11 2004-01-22 Vicuron Pharmaceuticals, Inc. Derives de n-hydroxyamide ayant une activite anti-bacterienne
CA2826033A1 (fr) * 2011-01-21 2012-07-26 (Inserm) Institut National De La Sante Et De La Recherche Medicale Methodes et kits pour la prediction du risque d'insuffisance respiratoire, d'insuffisance renale ou de thrombopenie chez un patient septique par mesure de la concentration sanguine d'endocan
WO2015017354A1 (fr) * 2013-07-29 2015-02-05 University Of Houston System Gaz organiques volatils utilisés en tant qu'indicateurs biologiques du rejet de greffon

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010652A1 (fr) * 1989-03-09 1990-09-20 Dana Farber Cancer Institute Procede de traitement d'infections virales a l'aide de lfa-1
WO1995025173A1 (fr) * 1994-03-14 1995-09-21 The Scripps Research Institute Procede d'identification d'inhibiteurs d'activation de l'integrine
WO1996024063A1 (fr) * 1995-01-30 1996-08-08 The General Hospital Corporation Procedes d'identification d'antagonistes de l'integrine
WO2000039081A2 (fr) * 1998-12-29 2000-07-06 Abbott Laboratories Composes anti-inflammatoires et immunosuppresseurs inhibant l'adhesion cellulaire

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010652A1 (fr) * 1989-03-09 1990-09-20 Dana Farber Cancer Institute Procede de traitement d'infections virales a l'aide de lfa-1
WO1995025173A1 (fr) * 1994-03-14 1995-09-21 The Scripps Research Institute Procede d'identification d'inhibiteurs d'activation de l'integrine
WO1996024063A1 (fr) * 1995-01-30 1996-08-08 The General Hospital Corporation Procedes d'identification d'antagonistes de l'integrine
WO2000039081A2 (fr) * 1998-12-29 2000-07-06 Abbott Laboratories Composes anti-inflammatoires et immunosuppresseurs inhibant l'adhesion cellulaire

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HUTH, J. ET AL.: "NMR and mutagenisis evidence for an I domain allosteric site that regulates lymphocyte function-associated antigen 1 ligand binding", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 97, 9 May 2000 (2000-05-09), pages 5231 - 5236, XP000938664 *
SAWYER, J. SCOTT ET AL: "Synthetic and Structure/Activity Studies on Acid-Substituted 2-Arylphenols: Discovery of 2-[2-Propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)- hydroxyphenoxy]- propoxy]phenoxy]benzoic Acid, a High-Affinity Leukotrien B4 Receptor Antagonist", J. MED. CHEM. (1995), 38(22), 4411-32, XP000939042 *

Also Published As

Publication number Publication date
AU4192000A (en) 2000-10-23
WO2000060355A2 (fr) 2000-10-12
EP1175615A2 (fr) 2002-01-30

Similar Documents

Publication Publication Date Title
AU5782900A (en) Secure, limited-access database system and method
AU2567100A (en) Automated file pruning
ZA200000079B (en) Driver, fastener and forming tool.
AU5279100A (en) E1 endoglucanase variants y245g, y82r and w42r
ZA9811936B (en) Patch panel.
AU2003210576A1 (en) A user authentication system and methods thereof cross reference to related applications.
GB9811082D0 (en) Improvements in phase-separation etc.members
AU2002234143A1 (en) Identity insurance transaction method
AU7492500A (en) Protective topical composition, products including the same, and methods
AU2001290141A1 (en) Variable automated response system
AU4430199A (en) Tankyrase, a trfi binding protein
AU2467099A (en) A spreading, crushing or cutting device
MXPA01009915A (es) Inhibidores de lfa-1 que se unen a los icam y usos de los mismos.
WO2001098367A3 (fr) Peptides neuroactifs servant a traiter l'hypoxie et des etats apparentes
AU2543000A (en) Punching rivet
WO2000060355A3 (fr) Site de liaison regulateur de lfa-1 (antigene de la fonction leucocytaire 1) et utilisations correspondantes
AU2003259755A1 (en) Identity protection in a lan-universal radiotelephone system
AU2001272989A1 (en) Composting system
AU7938898A (en) Surface-treated steel sheet for battery case, battery case, and battery manufactured by using the case
AU2001276425A1 (en) Machine for planting stakes, poles or the like
AU2094401A (en) Automated bindery log extension
AU5208200A (en) Screwed connection, fastener for said connection and method for the production thereof
AU2002306326A1 (en) General-purpose autentication system in organization
GB0007933D0 (en) Assays,methods and means
AU5336398A (en) Method to produce multi-layer plates, the relative plant and multi-layer plates obtained therewith

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000921627

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000921627

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000921627

Country of ref document: EP